New diabetes shot shows promise in early safety trial
Disease control
Completed
This early-phase study tested a new long-acting injection called NEX-22A in 12 adults with type 2 diabetes. The main goal was to see how the drug moves through the body and whether it is safe. Participants received a single dose, and researchers measured drug levels and side effe…
Phase: PHASE1 • Sponsor: Nanexa AB • Aim: Disease control
Last updated May 15, 2026 11:56 UTC